Isovanillic acid protects mice against Staphylococcus aureus by targeting vWbp and Coa

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Paling FP, Wolkewitz M, Bode LGM et al. Staphylococcus aureus colonization at ICU admission as a risk factor for developing S. aureus ICU pneumonia. Clin. Microbiol. Infect. 23(1), 49.e49–49.e14 (2017).
  Google Scholar
• 2. Federspiel JJ, Stearns SC, Peppercorn AF et al. Increasing US rates of endocarditis with Staphylococcus aureus: 1999–2008. Arch. Intern. Med. 172(4), 363–365 (2012).
  MedlineGoogle Scholar
• 3. Johnson JR. Rifampin and methicillin-resistant Staphylococcus aureus bone and joint infections. Clin. Infect. Dis. 53(1), 98–99; author reply 99–100 (2011).
  MedlineGoogle Scholar
• 4. Naber CK. Staphylococcus aureus bacteremia: epidemiology, pathophysiology, and management strategies. Clin Infect Dis 48(Suppl. 4), S231–S237 (2009).
  MedlineGoogle Scholar
• 5. Cheung GYC, Bae JS, Otto M. Pathogenicity and virulence of Staphylococcus aureus. Virulence 12(1), 547–569 (2021).
  Medline CASGoogle Scholar
• 6. Na M, Hu Z, Mohammad M et al. The expression of von Willebrand factor-binding protein determines joint-invading capacity of Staphylococcus aureus, a core mechanism of septic arthritis. mBio 11(6), e02472–20 (2020).
  Medline CASGoogle Scholar
• 7. Kamfose MM, Muriithi FG, Knight T et al. Intravenous ceftriaxone versus multiple dosing regimes of intravenous anti-staphylococcal antibiotics for methicillin-susceptible Staphylococcus aureus (MSSA): a systematic review. Antibiotics (Basel) 9(2), 39–49 (2020).
  Medline CASGoogle Scholar
• 8. Mcdanel JS, Perencevich EN, Diekema DJ et al. Comparative effectiveness of beta-lactams versus vancomycin for treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections among 122 hospitals. Clin. Infect. Dis. 61(3), 361–367 (2015).
  Medline CASGoogle Scholar
• 9. Tu H, Xu F, Cheng Y et al. Proteomic profiling of the endogenous peptides of MRSA and MSSA. PeerJ 9, e12508 (2021).
  MedlineGoogle Scholar
• 10. Klein EY, Zhu X, Petersen M et al. Methicillin-resistant and methicillin-sensitive Staphylococcus aureus hospitalizations: national inpatient sample, 2016–2019. Open Forum Infect. Dis. 9(1), ofab585 (2022).
  MedlineGoogle Scholar
• 11. Zheng Y, He L, Asiamah TK, Otto M. Colonization of medical devices by staphylococci. Environ. Microbiol. 20(9), 3141–3153 (2018).
  MedlineGoogle Scholar
• 12. Bjerketorp J, Jacobsson K, Frykberg L. The von Willebrand factor-binding protein (vWbp) of Staphylococcus aureus is a coagulase. FEMS Microbiol. Lett. 234(2), 309–314 (2004). •• Details that vWbp is a coagulase secreted by S. aureus, which has the ability to bypass the coagulation cascade, activate prothrombin and promote coagulation.
  Medline CASGoogle Scholar
• 13. Friedrich R, Panizzi P, Fuentes-Prior P et al. Staphylocoagulase is a prototype for the mechanism of cofactor-induced zymogen activation. Nature 425(6957), 535–539 (2003). •• Discovers and elucidates the mechanism by which staphylocoagulase induces prothrombin activation.
  Medline CASGoogle Scholar
• 14. Kroh HK, Panizzi P, Bock PE. Von Willebrand factor-binding protein is a hysteretic conformational activator of prothrombin. Proc. Natl Acad. Sci. USA 106(19), 7786–7791 (2009). • vWbp activates prothrombin through a substrate-dependent delayed kinetics mechanism.
  Medline CASGoogle Scholar
• 15. Panizzi P, Nahrendorf M, Figueiredo JL et al. In vivo detection of Staphylococcus aureus endocarditis by targeting pathogen-specific prothrombin activation. Nat. Med. 17(9), 1142–1146 (2011).
  Medline CASGoogle Scholar
• 16. Cheng AG, Mcadow M, Kim HK et al. Contribution of coagulases towards Staphylococcus aureus disease and protective immunity. PLoS Pathol. 6(8), e1001036 (2010).
  MedlineGoogle Scholar
• 17. Cawdery M, Foster WD, Hawgood BC, Taylor C. The role of coagulase in the defence of Staphylococcus aureus against phagocytosis. Br. J. Exp. Pathol. 50(4), 408–412 (1969).
  Medline CASGoogle Scholar
• 18. Thomer L, Schneewind O, Missiakas D. Multiple ligands of von Willebrand factor-binding protein (vWbp) promote Staphylococcus aureus clot formation in human plasma. J. Biol. Chem. 288(39), 28283–28292 (2013). • vWbp binds to multiple ligands in human blood to accelerate the formation of protective blood clots by S. aureus.
  Medline CASGoogle Scholar
• 19. Pappelbaum KI, Gorzelanny C, Grassle S et al. Ultralarge von Willebrand factor fibers mediate luminal Staphylococcus aureus adhesion to an intact endothelial cell layer under shear stress. Circulation 128(1), 50–59 (2013).
  Medline CASGoogle Scholar
• 20. Claes J, Vanassche T, Peetermans M et al. Adhesion of Staphylococcus aureus to the vessel wall under flow is mediated by von Willebrand factor-binding protein. Blood 124(10), 1669–1676 (2014).
  Medline CASGoogle Scholar
• 21. Ko YP, Flick MJ. Fibrinogen is at the interface of host defense and pathogen virulence in Staphylococcus aureus infection. Semin. Thromb. Hemost. 42(4), 408–421 (2016).
  Medline CASGoogle Scholar
• 22. Thomas S, Liu W, Arora S et al. The complex fibrinogen interactions of the Staphylococcus aureus coagulases. Front. Cell. Infect. Microbiol. 9, 106 (2019).
  Medline CASGoogle Scholar
• 23. Veloso TR, Chaouch A, Roger T et al. Use of a human-like low-grade bacteremia model of experimental endocarditis to study the role of Staphylococcus aureus adhesions and platelet aggregation in early endocarditis. Infect. Immun. 81(3), 697–703 (2013).
  Medline CASGoogle Scholar
• 24. Hijikata-Okunomiya A, Kataoka N. Argatroban inhibits staphylothrombin. J. Thromb. Haemost. 1(9), 2060–2061 (2003).
  Medline CASGoogle Scholar
• 25. Vanassche T, Verhaegen J, Peetermans WE et al. Dabigatran inhibits Staphylococcus aureus coagulase activity. J. Clin. Microbiol. 48(11), 4248–4250 (2010).
  Medline CASGoogle Scholar
• 26. Khadem S, Marles RJ. Monocyclic phenolic acids; hydroxy- and polyhydroxybenzoic acids: occurrence and recent bioactivity studies. Molecules 15(11), 7985–8005 (2010).
  Medline CASGoogle Scholar
• 27. Tung YT, Wu JH, Kuo YH, Chang ST. Antioxidant activities of natural phenolic compounds from Acacia confusa bark. Bioresour. Technol. 98(5), 1120–1123 (2007).
  Medline CASGoogle Scholar
• 28. Zhong H, Ruan JL, Yao QQ. Two new 4-arylcoumarins from the seeds of Calophyllum polyanthum. J. Asian Nat. Prod. Res. 12(7), 562–568 (2010).
  Medline CASGoogle Scholar
• 29. Li CY, Lee EJ, Wu TS. Antityrosinase principles and constituents of the petals of Crocus sativus. J. Nat. Prod. 67(3), 437–440 (2004).
  Medline CASGoogle Scholar
• 30. Saroglou V, Karioti A, Rancic A et al. Sesquiterpene lactones from Anthemis melanolepis and their antibacterial and cytotoxic activities. Prediction of their pharmacokinetic profile. J. Nat. Prod. 73(2), 242–246 (2010).
  Medline CASGoogle Scholar
• 31. Warner EF, Zhang Q, Raheem KS et al. Common phenolic metabolites of flavonoids, but not their unmetabolized precursors, reduce the secretion of vascular cellular adhesion molecules by human endothelial cells. J. Nutr. 146(3), 465–473 (2016).
  Medline CASGoogle Scholar
• 32. Delgado-Valverde M, Valiente-Mendez A, Torres E et al. MIC of amoxicillin/clavulanate according to CLSI and EUCAST: discrepancies and clinical impact in patients with bloodstream infections due to Enterobacteriaceae. J. Antimicrob. Chemother. 72(5), 1478–1487 (2017).
  Medline CASGoogle Scholar
• 33. Li B, Jin Y, Xiang H et al. An inhibitory effect of dryocrassin ABBA on Staphylococcus aureus vWbp that protects mice from pneumonia. Front. Microbiol. 10, 7 (2019).
  MedlineGoogle Scholar
• 34. Sperber WH, Tatini SR. Interpretation of the tube coagulase test for identification of Staphylococcus aureus. Appl Microbiol 29(4), 502–505 (1975).
  Medline CASGoogle Scholar
• 35. Gao K, Oerlemans R, Groves MR. Theory and applications of differential scanning fluorimetry in early-stage drug discovery. Biophys Rev 12(1), 85–104 (2020).
  MedlineGoogle Scholar
• 36. Macarthur Clark JA, Sun D. Guidelines for the ethical review of laboratory animal welfare People's Republic of China National Standard GB/T 35892-2018 [Issued 6 February 2018 Effective from 1 September 2018]. Animal Model Exp. Med. 3(1), 103–113 (2020).
  MedlineGoogle Scholar
• 37. Cooper GF, Aliferis CF, Ambrosino R et al. An evaluation of machine-learning methods for predicting pneumonia mortality. Artif. Intel. Med. 9(2), 107–138 (1997).
  Medline CASGoogle Scholar
• 38. Knapp S, Wieland CW, Van ‘T Veer C et al. Toll-like receptor 2 plays a role in the early inflammatory response to murine pneumococcal pneumonia but does not contribute to antibacterial defense. J. Immunol. 172(5), 3132–3138 (2004).
  Medline CASGoogle Scholar
• 39. Krishna SN, Luan CH, Mishra RK et al. A fluorescence-based thermal shift assay identifies inhibitors of mitogen activated protein kinase kinase 4. PLOS ONE 8(12), e81504 (2013).
  MedlineGoogle Scholar
• 40. Yang X, Cheng X, Tang Y et al. The role of type 1 interferons in coagulation induced by Gram-negative bacteria. Blood 135(14), 1087–1100 (2020).
  Medline CASGoogle Scholar
• 41. Guggenberger C, Wolz C, Morrissey JA, Heesemann J. Two distinct coagulase-dependent barriers protect Staphylococcus aureus from neutrophils in a three dimensional in vitro infection model. PLoS Pathog 8(1), e1002434 (2012). •• vWbp and Coa form a concentrically structured fibrin barrier at the bacterial periphery, protecting S. aureus from phagocytosis by neutrophils.
  Medline CASGoogle Scholar
• 42. Malachowa N, Kobayashi SD, Porter AR et al. Contribution of Staphylococcus aureus coagulases and clumping factor A to abscess formation in a rabbit model of skin and soft tissue infection. PLOS ONE 11(6), e0158293 (2016).
  MedlineGoogle Scholar
• 43. Vanassche T, Peetermans M, Van Aelst LN et al. The role of staphylothrombin-mediated fibrin deposition in catheter-related Staphylococcus aureus infections. J. Infect. Dis. 208(1), 92–100 (2013).
  Medline CASGoogle Scholar
• 44. Thomer L, Emolo C, Thammavongsa V et al. Antibodies against a secreted product of Staphylococcus aureus trigger phagocytic killing. J. Exp. Med. 213(3), 293–301 (2016).
  Medline CASGoogle Scholar
• 45. Trivedi U, Madsen JS, Everett J et al. Staphylococcus aureus coagulases are exploitable yet stable public goods in clinically relevant conditions. Proc. Natl Acad. Sci. USA 115(50), E11771–E11779 (2018).
  Medline CASGoogle Scholar
• 46. Crosby HA, Kwiecinski J, Horswill AR. Staphylococcus aureus aggregation and coagulation mechanisms, and their function in host-pathogen interactions. Adv. Appl. Microbiol. 96, 1–41 (2016).
  Medline CASGoogle Scholar
• 47. Mcadow M, Dedent AC, Emolo C et al. Coagulases as determinants of protective immune responses against Staphylococcus aureus. Infect. Immun. 80(10), 3389–3398 (2012).
  Medline CASGoogle Scholar
• 48. Baell JB, Holloway GA. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J. Med. Chem. 53(7), 2719–2740 (2010).
  Medline CASGoogle Scholar